Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers

Chemotherapy

Volumn 48, Issue 4-5, 2002, Pages 217-223

  Perret, C ^a   Lenfant, B ^a   Weinling, E ^a   Wessels, D H ^b   Scholtz, H E ^b   Montay, Guy ^a   Sultan, E ^a  

^a SANOFI   (France)

^b FARMOVS Research Centre   (South Africa)

Author keywords

Bioavailability; Elderly; Healthy volunteers; Pharmacokinetics; Telithromycin

Indexed keywords

DRUG METABOLITE; RU 76363; TELITHROMYCIN; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIRST PASS EFFECT; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZATION; SINGLE DRUG DOSE; SORE THROAT; TASTE DISORDER; TINNITUS; VOLUNTEER; AGE DISTRIBUTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE REGIMEN; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL;

EID: 0036911498     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066766     Document Type: Article

References (10)

1. Lenfant B, Sultan E, Wable C, Pascual H, Meyer BH: Pharmacokinetics of 800-mg once-daily oral dosing of the ketolide, HMR 3647, in healthy young volunteers; in: Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, American Society of Microbiology, 1998.
2. Sultan E, Lenfant B, Wable C, Pascual M-H, Meyer B: Pharmacokinetic profile of the new ketolide HMR 3647 800 mg once daily in elderly volunteers. J Antimicrob Chemother 1999;44(suppl A):54.
3. Bryskier A, Agouridas C, Chantot JF: Ketolides: New semisynthetic 14-membered-ring macrolides; in Zinner SH, Young LS, Acar JF, Neu HC (eds): Expanding Applications for the New Macrolides, Azalides and Streptogramins. New York, Marcel Dekker, 1997.
4. Agouridas C, Bonnefoy A, Chantot JF: In vivo antibacterial activity of HMR 3647, a novel ketolide highly active against respiratory pathogens; in: Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, American Society of Microbiology, 1997.
5. Sultan E, Namour F, Mauriac C, Lenfant B, Scholtz H: The ketolide antimicrobial, HMR 3647, is metabolised and eliminated mainly in faeces in man. J Antimicrob Chemother 1999;44(suppl A):54.
6. Somogyi AA, Bochner F, Hetzel D, Williams DB: Evaluation of the intestinal absorption of erythromycin in man: Absolute bioavailability and comparison with enteric coated erythromycin. Pharm Res 1995;12:149-154.
7. Chu S-Y, Deaton R, Cavanaugh J: Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob Agents Chemother 1992;36:1147-1150.
8. Foulds G, Shepard RM, Johnson RB: The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(suppl A):73-82.
9. Brook I: Pharmacodynamics and pharmacokinetics of spiramycin and their clinical significance. Clin Pharmacokinet 1998;34:303-310.
10. Namour F, Wessels DH, Pascual M-H, Reynolds D, Sultan E, Lenfant B: Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob Agents Chemother 2001;45:170-175.